Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
November 5, 2026
Earnings Call Speaker Segments
Lawrence Keusch
executiveHello everybody, and thanks for joining us for Teleflex Incorporated's Third Quarter 2026 Earnings Conference Call. You'll find the press release and the slides accompanying today's call on our website at teleflex.com. Just a reminder that a replay will be available on our website as well. Anyone who'd like to access that replay can find the details in this morning's press release. Joining me today are Jason Weidman, our President and Chief Executive Officer, and John Deren, our Executive Vice President and Chief Financial Officer. Jason and John will each deliver prepared remarks, and following that, we'll open things up for Q&A. Before we start, I want to remind everyone that certain topics we'll discuss on this conference call will include forward-looking statements about future events, as described in the slides posted in the Investor Relations section of the Teleflex website. Please be advised that these statements are indeed forward-looking by nature and carry risks and uncertainties, so actual events or results could differ materially. The factors that might cause actual results or events to differ materially include, but are not limited to, those referenced in our press release today and in our SEC filings, including our Form 10-K, which is available on our website. At this point, I'll hand things over to Jason so he can share his comments.
Jason Weidman
executiveThank you, Larry, and good morning to all of you. I'd like to open today by walking through the quarter's key points. Teleflex posted a robust third quarter, recording pro forma adjusted constant currency revenue growth of 3% alongside an adjusted operating margin of 25%. Even if you set aside the gain from the IEEPA tariff refund received in 2026, adjusted margins still showed mild expansion, and earnings per share rose. Vascular and Surgical kept up its solid growth, and Interventional went back to positive growth, an improvement over what it delivered in the second quarter. Beyond that, we continued giving money back to shareholders by buying up another $350 million in stock — which is $100 million more than the figure we'd shared before — during the stretch from the beginning of Q3 up through today. John will walk through how we're lifting our adjusted EPS outlook for the entire year, a change that mirrors third quarter momentum and our view of how the remaining months will play out. It's been about five months since I took on the CEO role at Teleflex. During that time I've conducted an in-depth examination of the company, devoted substantial hours to touring facilities and meeting customers across the globe, and kept us zeroed in on the operational priorities that count the most. On the prior call, I promised I'd have more to say by now about how I see the business and where we're headed. Although I still feel it's early in my time here, I want to offer a few insights, especially regarding our growth strategy, before moving to our priorities and expectations going forward. As we've said before, Teleflex is undergoing an enormous transformation, and I want to thank our employees for the enormous effort, commitment, and additional work they've contributed to keep pushing that transformation ahead. Now that I've seen firsthand what it truly takes, I can say I'm extremely proud of our team. We've consistently described 2026 as a transition year, and we've made meaningful progress and hit concrete milestones, among them merging the vascular intervention and Teleflex interventional access teams, completing the OEM divestiture, and giving substantial capital back to shareholders. We believe these steps will strengthen our financial profile in 2027 through higher adjusted margins, reduced interest expense, a smaller share count, and a meaningful step-up in adjusted earnings per share. Despite the progress, more work remains before we generate the long-term growth I'm confident Teleflex is capable of. I have three top priorities. To start, we're reinforcing the base by executing the transformation — that means wrapping up the acute care and interventional urology divestiture and completing integration of our interventional business, so it sits in a position for sustainable growth. Next, we're stepping up organizational effectiveness by getting a global business unit structure fully established and making the way we operate simpler. Third, we're raising our growth profile by advancing innovation in the key growth drivers, all within a balanced capital allocation framework. Taken together, these priorities add up to building a Teleflex that is more focused, more agile, and more oriented toward growth — a company that sits nearer to its customers, moves faster in its operations, and is better positioned to deliver meaningful innovation and sustainable growth. Starting with priority one, clearly the most important over the near term, we must fully carry out the foundational pieces of our transformation so we deliver a newly focused Teleflex that is built to grow. On the operational side, our immediate focus is to successfully complete the interventional integration. Although this has taken longer than we initially planned, we achieved notable progress during the third quarter on the three transition dynamics I laid out in August, and I'll go through some of those details when I discuss Interventional's results a bit later. Our future success with Interventional comes down to focus and execution. I'm firmly convinced that Interventional is now set up with the correct strategy, excellent products, and the right team to deliver better growth in the coming years. To reinforce the leadership of this business, we recently brought in Jason Fontana, who took on the role of President and General Manager of Interventional as of September 14th. His leadership background covers over twenty years in interventional markets, including global P&L accountability, commercial strategy, market development, innovation, and business growth. Jason and I have been acquainted and have worked together for roughly twenty years, and I have great confidence in his capacity to steer this business through a successful integration and beyond. Another essential element of delivering on our transformation is finishing the divestiture of acute care and interventional urology. Let me state plainly that our confidence in getting this deal done is high. The FTC, as we've said before, sent a second request back in March. What they're examining is a narrow slice where our products and the acquirer's current lineup happen to coincide — something well-defined and within our ability to handle. Keep in mind that Intersurgical is driving this process, and we're collaborating closely with them to back it up. We're still pushing to finalize by the end of the year, though exactly when that happens depends on regulators and might slip into 2027; even so, let me repeat that our belief in closing the whole transaction hasn't wavered, and the headway being made gives us encouragement. To fully seize the advantages of the leaner, more focused Teleflex we're creating, a change in how we operate is essential. That brings me to my second priority: speeding up our organizational effectiveness. In the past, Teleflex was set up by geography, which frequently produced differing approaches across regions of the world. As time passed, it generated a complicated matrix in which accountability was dispersed among too many individuals, and goals were not always in alignment. Frankly, it also produced a substantial process burden that sometimes diverted our attention from the customer and made us slower. To clear away the things standing in the way of execution, we're in the process of introducing a worldwide business unit framework and simplifying how we operate—all of which is meant to bring sharper focus on customers, clearer accountability, and quicker decisions. On that front, this quarter marks a big step for us. We now run and report through three worldwide business units: Vascular, Interventional, and Surgical. These BUs now have a clear view across the world, along with the authority to put their resources where they'll do the most good so growth is maximized. Every business will be responsible for its own strategy, its own resources, and its own results. Our goal is straightforward: put customers at the heart of what we decide, give our global businesses the authority to lead, and ensure our corporate functions assist them in moving quicker and executing more effectively. Simultaneously, we've started several efforts designed to cut down on process complexity and streamline how we operate. All of this together amounts to yet another significant transition for the company, for the people who work here, and for how we get things done. I can share that our employees are truly energized. There's a firm conviction that we're able to improve things so it gets simpler for our teams to accomplish their work and to serve customers more effectively. Priority three for me is lifting how our company grows—pushing innovation across the main growth drivers while keeping capital allocation balanced. We already said we'd redeploy proceeds from divestitures: that covers $1 billion for repurchases of shares plus $800 million to pay down debt. Past that, our capital deployment approach means putting money into R&D and capex so organic growth gets funded, keeping the balance sheet strong, and directing surplus capital toward buybacks or, down the road, M&A.
Jason Weidman
executiveOn organic growth, historically the bulk of our R&D dollars went into sustaining products and iterations, and planning cycles tended to be shorter term. That's shifting. We've lifted R&D investment from the roughly 5% to 6% of revenue we spent in the past to almost 8%, and more of that funding now supports substantive innovation. One example is Freezsolve, our resorbable magnesium scaffold. As we shared this summer, enrollment in the BIOMAG-II trial wrapped up ahead of schedule, with the data read-out expected in late 2027, and BIOMAG-III, our US pivotal trial, is underway. Just recently, we finished enrolling patients in the European BIOMAG-I LL clinical trial. That study is evaluating how well extended-length 35 and 40 Freezsolve resorbable scaffolds work clinically and how safe they are in long lesions, which are still some of the toughest lesion subsets in PCI. Also, we were thrilled to share two weeks ago that the FDA granted Freezsolve breakthrough device designation for PCI. That recognition highlights how novel our approach is and gives us closer engagement with the agency as we advance the program. EasyPlas is another strong example of organic innovation where we foresee substantial potential ahead. Late July's clearance marked a major milestone for Teleflex, and during our prior call, a number of you inquired about how we view the opportunity. Back in August, I noted that we still had much to learn, and across the quarter since, we've gained considerable insight. EasyPlas stands as the first and only freeze-dried plasma holding FDA licensure, and customer interest has run high; it tackles a substantial unmet need. Currently, frozen plasma represents the standard of care, requiring frozen storage and thawing prior to use. That restricts the locations where plasma can be deployed and the speed at which it can reach a patient. EasyPlas keeps at room temperature and can be reconstituted in minutes. This means plasma can be accessed on the battlefield, in air and road ambulances, and at trauma centers seeking instant plasma availability in any situation without thawing delays. Our flexible bag also stands as a significant advantage compared with the glass container formats we anticipate from future freeze-dried competitors. As the sole licensed product offering these characteristics, we hold a first-mover advantage, and we believe EasyPlas will establish the benchmark by which any later entrant is judged. Regarding market size, I mentioned last quarter that I preferred to conduct a thorough assessment before committing to a figure. We still have work ahead of us, yet we now feel confident that, over the long term, the US market could be worth at least $200 million and serve as a meaningful growth driver for Teleflex. I want to be clear about the pace. Our first priority is the US government and military, which we expect will represent the majority of our current manufacturing capacity. We are actively engaged with the Department of War, and those conversations continue to progress. From this point forward, we still need to go through procurement solicitation, contract negotiation, and execution before commercial delivery happens. Our expectation remains that EasyPlas revenue will be immaterial in 2026 and will start contributing in 2027. Beyond that, we expect revenue to build gradually over the first few years. We will have to develop this market ourselves, and ramping up manufacturing for a biologic this complex is a major endeavor, not a routine addition of capacity. Achieving a substantial increase in supply will require considerable work over multiple years, and we will be deliberate about the order in which we make those investments. This is a long-term opportunity that we are developing carefully, and our focus is on positioning Teleflex to capture it over time. More broadly, looking ahead, resources will be directed disproportionately toward our strongest growth opportunities, including through opportunistic tuck-in acquisitions that align with our three core businesses and our capital allocation framework. We're refining how we assess opportunities and keep tabs on execution, and our board's growth and operating committee is providing oversight for that work. We've also brought relevant know-how onto the board itself. Sean Salmon became a member of our board of directors on September 8th. Sean has over thirty years of worldwide leadership experience across the medical device and pharmaceutical sectors, among it more than two decades with Medtronic. In his latest role, he was executive vice president and president of the company's cardiovascular portfolio, a global business that posted roughly $12.5 billion in fiscal 2025 revenue, and there he played a key part in shaping the growth strategy. I'm looking forward to collaborating with Sean and the full board so we can keep advancing our strategy, ensure our priorities get executed, and lift growth at Teleflex. Next, we'll turn to the detailed results for our third quarter continuing operations along with the revised financial guidance for 2026. Unless I say otherwise, every growth figure I cite reflects a year-over-year pro forma adjusted constant currency comparison for the third quarter of 2026 continuing operations. Teleflex brought in revenues of $567.8 million in the third quarter, which represents a 0.2% increase year-over-year on a GAAP basis and a 3.0% increase on a pro forma adjusted constant currency basis. During the quarter, our top line showed sustained healthy expansion in both Vascular and Surgical, while the Interventional segment felt the effects of integration and restructuring work tied to the VI business. Adjusted EPS for the third quarter came in at $2.63, up 39.2% compared with a year ago and better than we had anticipated. Let's now look more closely at how revenue played out in the third quarter. Turning first to Vascular, sales reached $243.5 million, rising 4.6% year over year, with the main drivers being our intraosseous portfolio, hemostatic products, and peripheral access products. Growth, as we had expected, came in a bit slower than during the first half, reflecting some distributor inventory destocking as conditions normalized after the lidocaine recall from earlier in the year. For Surgical, we posted $114.0 million in revenue, up 5.1%, with the main drivers being solid results in ligation clips and skin stapling. Growth in Surgical also cooled versus the first half, as we had expected, given the difficult comparisons stemming from our new instrument portfolio ramping up in mid-2025. In Interventional, revenue reached $210.3 million, a 0.2% gain. Growth was still weighed down by integration and restructuring efforts tied to the VI acquisition that remain in progress, but we did see an improvement from the second quarter. Several categories beat expectations, including complex catheters, hemostatic products, right heart catheters, and OnControl. In August, I described several transition-related issues affecting the Interventional business that, in our view, would turn out to be short-lived. We made good progress in the third quarter, with clear evidence that our mitigation efforts are working, and we are now moving consistently toward better results. I'll provide a bit more detail. The order-to-cash transition is largely complete at this point. During Q3, we pinpointed what had caused the customer and process disruption and acted quickly to put corrective measures in place. As the third quarter ended, about 90% of vascular intervention customers had been moved onto the Teleflex ordering platform, and we anticipate that substantially all customers will complete the switch soon. Regarding distributors, the bulk of the indirect vascular intervention business has now shifted to Teleflex distributors and sits under our control, which has given us improved visibility and predictability into the business.
Jason Weidman
executiveAlthough certain distributor transition efforts are still ongoing, we now possess the visibility needed to put in place broader action plans that will generate consistent gains in this portion of the business. Regarding our sales force, substantial headway has been achieved in staffing vacant territories, and the number of unfilled roles has fallen 63% versus its highest point. Bringing new representatives up to full productivity will require time, yet the caliber of the people we have brought on board, along with the enthusiasm shown for becoming part of Teleflex, gives me confidence—a reflection of how strong our portfolio is, the culture we are cultivating, and what lies ahead. With Jason Fontana at the helm, we anticipate finishing the transition work that remains, honing our emphasis on new product possibilities—among them differentiated technologies such as Freezsolve—and speeding up growth as time goes on. Our attention stays fixed on setting Interventional up for success over the long term, and my confidence that our portfolio and our team can achieve that is unchanged. At this point, I will hand the call to John, who will walk through our financial results in greater detail. John?
John Deren
executiveThanks, Jason, and good morning. Every figure I cite will be on a continuing operations basis for 2026. Because of how discontinued operations have been reclassified, the historical continuing operations numbers include the effect of stranded costs across all periods shown. After Jason covers revenue, I'll start with margins. Adjusted gross margin for the third quarter of 2026 came in at 66.8%. The 450 basis point year-over-year gain reflects a 290 basis point benefit in the quarter from a refund tied to IEEPA tariff payments made in 2026, along with foreign currency exchange rate fluctuations, partly offset by higher quality remediation charges. For Q3 2026, adjusted operating margin reached 25%, up 300 basis points from a year earlier. Gross margin expansion drove that gain, though it was partially offset by investments in the business and increased incentive compensation, which mirrors both a smaller accrual in last year's quarter and better results this year. Adjusted net interest expense totaled $18.9 million in Q3, compared with $30 million a year ago. The year-over-year decrease stems primarily from reduced average debt outstanding, as we used part of the cash proceeds from the OEM divestiture to pay down debt. Our adjusted tax rate in Q3 2026 was 11.1%, versus 9.3% in the prior year. The increase compared with a year earlier stems primarily from a less favorable jurisdictional mix during the quarter and extra cost tied to capitalizing certain R&D expenditures. On the bottom line, adjusted earnings per share came to $2.63 for the third quarter, up 39.2% from a year earlier. That year-over-year result was driven largely by greater sales volume, reduced interest expense, and fewer shares outstanding, along with the benefit of tariff refunds. When the third quarter ended, cash, cash equivalents, and restricted cash equivalents totaled $444.3 million, versus $402.7 million at year-end 2025. By the close of the quarter, net leverage stood at roughly 1.40 times, a decline from 2.8 times in the second quarter, primarily due to paying down debt after we finished the OEM strategic divestiture. Now to our approach for allocating capital. We continue to be dedicated to giving cash back to shareholders through the $1 billion share repurchase authorization we announced earlier, as well as reducing debt by $800 million. From July 1 onward, we have repurchased common stock worth about $350 million, which exceeded our projections when we held the second quarter earnings call. These buybacks consisted of two pieces: our accelerated share repurchase program of $250 million, which is now finished, plus another $100 million bought in the open market. Together that works out to roughly 2.7 million shares, with an average price of $128.96 per share. The guidance we've issued for 2026 continuing operations has been updated to account for these repurchases through today's call, though it doesn't factor in any further buybacks over the rest of the year. As of November 5th, 2026, $400 million was still available to the company under the existing authorization. During the third quarter, we paid off the $700 million term loan A-2 associated with acquiring the vascular intervention business, and we also reduced a portion of our revolver. Let's turn now to how we're framing the financial guidance. As we've noted previously, several temporary items will show up in 2026 results because of the divestitures we've undertaken strategically, and those items will weigh on near-term performance; we expect them to be offset once both deals are completed. Accordingly, we believe 2027 will give a better picture of the underlying business, and over time that should produce a clearer financial profile, with meaningful gains in adjusted margins, interest expense, and adjusted earnings per share. We've also already announced the start of a restructuring plan spanning multiple years, which we expect to yield about $50 million in annual pre-tax cost savings by the time it wraps up in mid-2028. Those restructuring efforts are proceeding on schedule, kicked off in the first quarter of 2026, and our guidance still incorporates the savings they are expected to generate. We're also spotting further chances to cut costs, since we stay dedicated to reducing the stranded costs connected to the strategic divestitures. With that in mind, I'll go through the factors that will shape our 2026 results. To start, our 2026 assumptions still incorporate the effect of stranded costs, partly offset by transition service agreements linked to the OEM strategic divestiture's close. Of note, the transition services and manufacturing service agreements connected to the acute care and interventional urology strategic divestiture are wider in scope than the OEM ones, since the buyer needs more support, and that will support our adjusted margin expansion in 2027 as we offset stranded costs. Second, how quickly we complete the strategic divestiture of acute care and interventional urology will somewhat determine how much additional capital we can put to work during the rest of 2026. Third, we've revised our 2026 adjusted gross margin assumption to reflect IEEPA tariff refunds, which reduced adjusted cost of sales in the third quarter by $16.5 million. Looking ahead to 2027 and beyond, we expect that our capital deployment actions, together with the effects of the transition services and manufacturing service agreements and our work to further reduce stranded costs and right-size the organization, will drive a meaningful rise in adjusted operating income, adjusted margins, and adjusted EPS. Now, an update on our 2026 guidance. Keep in mind that our 2026 outlook reflects continuing operations only, leaving out the acute care, interventional urology, and OEM businesses. For 2026, we still anticipate pro forma adjusted constant currency revenue growth between 3.5% and 4.5%. On adjusted earnings per share, we're lifting the 2026 range to $7.50 to $7.75, up from the $6.90 to $7.20 we guided to previously. This outlook incorporates third quarter results, our updated expectations for the remainder of the year, common stock repurchases made through today's conference call date, and a $0.31 benefit to continuing operations related to 2026 from IEEPA tariff refunds. Our adjusted EPS guidance does not factor in any gain from the strategic divestiture of acute care and interventional urology, nor the expected upside from additional share buybacks. By 2027 and afterward, we anticipate these moves will yield a substantially smaller share count along with markedly lower interest expense. Taken as a whole, we expect buybacks plus balance sheet deleveraging to generate considerably stronger adjusted EPS beginning in 2027. Also, when you're modeling, here are a few things to keep in mind: the foreign exchange impact for 2026 is now expected to benefit reported revenue by about $9 million to $10 million, compared with $14 million previously; we now expect an adjusted operating margin of roughly 20% for 2026, and that figure includes the $16.5 million effect of the IEEPA tariff refund on gross margin. Once the divestitures of acute care and interventional urology have closed, we're confident that operating margin will come in at approximately 23% in year one, since manufacturing and transition service fees will offset stranded costs. Going forward, we see opportunities over the long term to improve the steady-state operating margin through operating leverage from revenue growth and other cost-savings initiatives, partly offset by continued investment in the business. Moving on to the assumptions below the line: on net interest expense, our full-year 2026 expectation remains roughly $85 million. For adjusted tax rate in 2026, we now anticipate about 11.5%, compared with the approximately 12.25% we cited before. And finally, for 2026 we now expect shares outstanding of roughly 42.5 million, which reflects the share repurchases completed so far. That concludes my prepared remarks; at this point I'd like to return the call to Jason for his closing commentary.
Jason Weidman
executiveThanks, John. To wrap up, I want to leave you with three main points from the third quarter of 2026. First, Teleflex posted a strong third quarter, with adjusted margins expanding and adjusted earnings per share growing. Vascular and Surgical held up well, and Interventional is headed in the right direction. With that performance and how we see the rest of the year, we're keeping our pro forma adjusted constant currency revenue growth outlook unchanged and lifting our full year adjusted EPS guidance for 2026. Second, we made real progress on our transformation this quarter. The interventional integration is advancing with new leadership now in place, and we're still confident we'll complete the acute care and interventional urology divestiture. We're also pushing forward on longer-term growth opportunities through innovations such as EasyPlas and Freezsolve. Third, we have a clear path forward resting on three priorities: strengthening our foundation, accelerating our organizational effectiveness, and elevating our growth profile as we fund our innovation engine. Along with our capital return and debt reduction — including the planned completion of our $1 billion share repurchase authorization after the acute care and interventional urology divestiture closes — these priorities position us for a meaningful step-up in adjusted operating margin and earnings per share in 2027 and sustainable growth beyond. There's still work ahead, but we're building a more focused, agile, and growth-oriented Teleflex, and I'm confident in our team's ability to deliver on the opportunity in front of us; that concludes my prepared remarks. Now I'd like to hand the call back to the operator for Q&A.
Vik Chopra
analystMorning, and thanks for taking my questions — congratulations on a solid quarter. I've got two. First: Interventional came back to modestly positive growth, which was encouraging, but I believe you mentioned the integration disruption is still ongoing. So I'm wondering how we ought to view that business's quarterly growth trajectory across 2027, and when you'd anticipate it getting back to at least the company average growth — and then I have a quick follow-up, please.
Jason Weidman
executiveSure, appreciate the question, Vik. So, when it comes to Interventional, what we're aiming for is steady, ongoing improvement — positioning the business for 2027, returning it to growth in the market, and generally setting it up to succeed over the long haul. And in Q3 we made real, tangible progress on that front, which we're pleased about. Perhaps I can go a bit deeper into the specifics of what moved forward, especially in those three areas we discussed in the prepared remarks and brought up last time. On the OTC transition side, as things stand, roughly 90% of the customers — the VI customers — are now on the Teleflex ordering system. During the previous call, we mentioned that even when system migrations go smoothly, moving customers over can still cause disruption and uncertainty. To illustrate this concretely, in Q2, when we did the transition in Europe, 7% of our orders went astray, and by the time we moved through Q3 and came out of it, that figure had dropped well under 1% — we achieved substantial improvement on that front. Regarding the distributor transition, while our indirect business was still operating through the old Biotronik distributors and/or under legacy Biotronik arrangements and contracts, we lacked truly close visibility into what was happening. In particular, many of these parties had little incentive to work collaboratively with us if they weren't going to be the long-term distributor. Likewise, we completed a huge transition here in the quarter; so 87% of that indirect business is now within our control, and we now have great visibility and can plan that business much better; we've turned a quarter and I believe that'll be on the upswing. Last, regarding our sales organization—an issue that showed up mostly in the US—open roles came down by 62% to 63%. In terms of quality, though, the caliber of hires has been excellent, and we're now hearing from some of the top reps in the business, even in areas where no territory is available. We feel very good about where this is heading. With the right portfolio, the right strategy, and now the right leadership in place to push things forward, we expect steady gains throughout 2027.
Vik Chopra
analystThanks a lot for that thorough response. Should the acute care and interventional urology divestiture end up slipping into 2027, could you walk us through, at a high level, what that would mean for stranded costs, interest expense, debt reduction, repurchases, and the timing of any 2027 EPS benefits? Thank you.
John Deren
executiveGlad to take that one. First, we are continuing to push very hard to get this closed in Q4, and obviously that remains our hope. It is possible that it slips into 2027. What I'll say is I'd rather not speculate, if it does slip, on when that might be, but we feel confident about the first 12 months delivering that 23% op margin with all the factors you just listed. Whether I can speculate or begin laying out the math for you, I'm not sure. You've got all the components from us. You can think through how you would model that with a delay, I believe, but our confidence remains pretty solid that within that 12 months post-act of disposition we would reach our 23% margin guidelines.
Patrick Wood
analystFantastic. Thank you, guys. I'll begin with a really nerdy one, so my apologies, but Freezsolve — clearly, many of us were just at TCT, and there's a huge amount of chatter about sirolimus coronary balloons, and you know every player in that space too, but how do you view Freezsolve's position in the market relative to those? Given that it holds the vessel open throughout the absorption period, is there still potentially a superior solution, because obviously there's a lot of noise on that, and I'm just curious whether you see that impacting what Freezsolve is ultimately worth, one way or the other?
Jason Weidman
executivePatrick, thanks for asking. I enjoy the nerdy questions, particularly in the PCI market. Look, I think broadly, with the enthusiasm surrounding DCB, and at this meeting, another positive result from sirolimus-eluting balloons, I sort of credit that to interest in avoiding a permanent implant. It's that broader category. The world shifted toward DCBs when the first attempt at resorbable scaffolds failed, but the original vision and what people desired was a scaffold or a stent that went in and then disappeared. There was a reason why 30, 40 years ago, the world went from plain balloons to plain stents, and temporary scaffolding does offer advantages. I absolutely believe there's a place for Freezsolve, and I'd add that I was at TCT as well, and there was enormous excitement at the meeting for Freezsolve, for BIOMAG-II, and to see how the product performs versus DES, which we'll see in about a year.
Patrick Wood
analystGot it. And a quick follow-up—apologies if this was already covered earlier; I was bouncing around a bit. On the EasyPlas side, there's clearly a solid opportunity for you folks. If it began arriving somewhat quicker than expected, how does supply look? Could you ramp up quickly to meet demand, or do you think you're constrained on supply?
Jason Weidman
executiveThanks, Patrick. As we've mentioned, we view this as a strong long-term opportunity worth at least $200 million in the US, though it's a new market. Building it will take time; developing that market will take time. Our top priority, as we also noted on the previous call, is really serving the US government and US military, and we believe that near term—and actually through the mid term, the first couple of years—they will likely account for most of our capacity. That's genuinely going to be an excellent place for us to demonstrate its use and to help lay the early groundwork for developing that market.
Patrick Wood
analystCompletely understand. Thank you, Jason. Thank you all.
Jayson Bedford
analystMorning. Appreciate you taking our questions. Just on Interventional, I suppose there are quite a few moving pieces. When does the integration wrap up? Jason, I'd really like to hear your perspective on end market growth within that interventional business.
Jason Weidman
executiveAppreciate the question. As I mentioned earlier when answering the first question, what we're aiming for is really that continuous improvement, and we're seeing strong progress across all of those integration items. I don't view this as one single point in time, some specific date, where suddenly you go from zero to one. My view is that this is continuous improvement over time, just as we've discussed. Regarding end market growth, I'd say that in total, these are mid-single-digit markets, so clearly the opportunity for us is to over time, as well as to ensure we're positioning ourselves within the higher-growth and more attractive subsegments of the overall interventional market.
Jayson Bedford
analystThanks. And perhaps, as a follow-up on that same theme, could you somehow break out how growth looks in the VI or Biotronik business compared with the legacy Teleflex interventional business?
Jason Weidman
executiveWell, we don't provide guidance by individual product lines, and by now the VI business has been fully anniversaried within our total interventional business, but it's fair to state that the VI piece has done worse than the legacy business, since this stems from integration disruption.
Jason Weidman
executiveLet me start with that first item. Obviously, we know about the BD arrangement. BD is a far bigger business than ours, and their circumstances differ from ours, so as of right now we have nothing to share regarding a comparable deal to BD's. As for how we're thinking about 2027 with respect to tariffs —
John Deren
executiveYeah. Look, the way we've dealt with tariffs from the beginning — since liberation days — is we keep steering by whatever is in force at the moment. It's been really tough trying to predict what comes next, even with those 232 investigations out there. As things stand, what we see for this year is roughly a bit more than $30 million in tariffs, and at this point I'd anticipate roughly the same for 2027, and once we have more information, we'll share more with you.
Anthony Petrone
analystThank you, and good morning. I have one question about Interventional and one about EasyPlas. First, on Interventional, some headwinds from the Biotronik integration remain, so could you give a bit more detail on that integration: where are you behind schedule, where might you be ahead of schedule, and when will those integration headwinds finally be behind you? Then I have a quick follow-up on EasyPlas.
Jason Weidman
executiveAll right. Well, I believe I largely addressed this with the first question, which is that we reported the integration delays we were seeing last quarter. Looking ahead, what we aim to do is really ensure we demonstrate continuous improvement; we have put very tangible improvement measures in place across all three of those areas I identified last time. I walked through those during the first question, so our goal is to keep driving that improvement. We feel good about it; there is a lot of opportunity in this business. We have new leadership under Jason Fontana, who knows this business like the palm of his hand, and we have plenty of opportunities to gain share, to grow through geographic expansion and through new product introductions, and we feel good about the direction we are going.
Anthony Petrone
analystSorry about that. Regarding EasyPlas, I saw that the TAM opportunities went up to at least $200 million. I recall that a few years ago, when that asset was acquired, it stood at least $100 million. Could you say a bit about the higher TAM outlook for EasyPlas? Thanks.
Jason Weidman
executiveThanks for asking. Well, I wasn't around when the $100 million TAM was issued several years back, so what I can address with the most confidence is how we view it going forward, and when we examine the market, we grasp what the opportunity is, again, with the top priority being the military and government segment here in the US, plus limited penetration into the civilian market, and with pricing we consider reasonable, we arrived at a TAM of at least $200 million. Once more, I want to stress that this is a market development play. It's going to take time. This isn't something that happens overnight, and our top priority here is truly making sure we serve the US government and the US military and what their needs are, and that will account for the vast majority of our capacity for the first couple years.
Jason Bednar
analystGood morning, everyone, and thanks for taking the questions. I've got a few follow-ups here on some topics we touched on earlier. I'll take the first swing at Interventional. Jason, I realize you'd rather not go into much detail on guidance by segment, but I really want to tie this up neatly. You've mentioned the progress on the three VI integration dynamics, and that's genuinely encouraging. Given how things moved during the quarter, presumably conditions improved from August into September, and that then carried over into the fourth quarter. Is it fair for us to assume you're comfortable delivering sequential improvement in constant currency growth for the fourth quarter, with that momentum then building into 2027?
Jason Weidman
executiveSure. When we look at the guidance for 2026, let me step back for a moment. On the top line, to be clear, the only change to our guidance related to currency effects. Our constant currency guidance for the year, 3.5% to 4.5% growth, remains unchanged. Q3 came in largely as expected, our Q4 outlook is unchanged, and the range we have there reflects the range of outcomes we discussed last quarter. At the low end of the guidance, that would assume no improvement in Interventional, basically from that Q2 revenue number, and we have high confidence in our ability to hit the low end of the guidance. At the high end of the guidance, that would mean outperformance across our portfolio; for Interventional specifically, again, we don't guide by business, but I think it's safe to say we're targeting a modest sequential improvement in the interventional business quarter-over-quarter.
Jason Bednar
analystOkay, that helps a lot. Thank you. Now about EasyPlas — I want to try once more on the forward guidance side. How should we model what it brings in? You called it a meaningful revenue contributor in 2027. Does that mean a modest amount? Could you give us ranges, say 50 basis points or 100 basis points, so our models line up? And does it add to Teleflex's margins right away, or does it take a certain scale before that margin benefit shows up?
Jason Weidman
executiveAlright. To start with the revenue growth question: every new market needs time, and this completely new one is no exception. The expansion will be gradual and consistent as time goes on. We don't provide guidance by specific product line, and I won't narrow this down to particular figures, but I'll say again that we expect it to be immaterial in 2026. There will be a contribution in 2027, and then a modest one from that point onward, following that first bolus and the steady demand we anticipate from the government, which will consume most of our capacity. We'll begin developing that market, and then also begin expanding our capacity, which I believe will start showing more meaningful growth a few years out as both the market and capacity grow. What was the second part of the question?
Jason Bednar
analystDoes it add to margin right away, or do you need scale before margin improves? Oh, margin—sorry, thank you.
Jason Weidman
executiveAbout margins: look, with any product, when you first launch it, usually it takes some time before your margin reaches where you ultimately think it will be, obviously; that comes with volume. At the same time, price obviously dictates margin, and we haven't yet settled our final pricing, and that will largely be settled as we work through the contract negotiation with the US government, and we are still in that process right now, we don't have a final price decided on yet.
Mike Matson
analystAppreciate you fielding my questions. To start, I'd like to ask something that leans toward strategy. I understand the acute care and urology deal still has to close, and there's more debt to pay down and so on, but it really does sound as though you're thinking about pursuing some M&A further out. Reading between the lines here, it seems that would probably center on the Interventional category, bringing in faster-growing products there, more or less. Would that be a fair read? Given what you've laid out, Jason — bringing Jason Fontana on board and adding Sean Salmon to the board — it looks as though the company sees Interventional cardiology as where its future lies, so I'd like to hear your perspective on that.
Jason Weidman
executiveAbsolutely. The main point I want to make is that there’s substantial work ahead of us to finish several foundational items that are directly in front of us, so that is clearly our top priority. We have to ensure Interventional is completely integrated and that the business is performing as we anticipate. We also need to finish the acute care and interventional urology divestiture, as you mentioned. The TSAs and MSAs extend past that point. That effort doesn't stop once deals are finalized. At the moment we have a great deal of transformation underway, so I wouldn't expect any meaningful M&A activity in the near future. Once we get past that point and feel more confident about completing that foundational work, we will definitely examine chances to strengthen and bolster our three businesses. All three of our businesses strike us as attractive, and each has appealing adjacent opportunities we can go after, so we'll be evaluating them across the board. Interventional is certainly a major part of that. Plenty of appealing adjacent markets exist there, so opportunities will arise in that area, though chances will probably also emerge within our other businesses.
Mike Matson
analystThank you. And then, regarding EasyPlas specifically, that $200 million TAM you mentioned—would you be open to breaking that down between military or government applications and civilian ones? My recollection is that it was 50/50 back when it was $100 million, though I'm not sure whether that still holds.
Jason Weidman
executiveRight now, we're simply not going to delve into those specifics. This, I'd say, is a long-term opportunity, correct? It's something we'll build up gradually as time goes on. We intend to do it properly. Our goal is to make EasyPlas the market standard, and in the end, if penetration runs deep, the civilian market likely offers greater potential—but that's over the long term.
Travis Steed
analystHi, thanks for asking. I'd like to begin at a somewhat broader level first. You mentioned plans to lift the growth profile — that was roughly the wording you used — and I believe there are considerable synergies between Biotronik and the Teleflex sales force, and you could include items such as the Orsiro drug-eluting stent, cross-sell it, and pick up share. I'm just trying to understand the strategy here for how you intend to speed up growth, how long it takes before this is fully in place, and whether you can grow in line with your mid-single-digit markets, with the potential to exceed that over time? I also had a follow-up question.
Jason Weidman
executiveTravis, is your question specifically about Interventional, then?
Travis Steed
analystI am, yeah. Surely. Really just
Jason Weidman
executivethe
Travis Steed
analystSo, the synergies on the Interventional side.
Jason Weidman
executiveAll right. Look, I don't want to sound like a broken record here, but once again I'd say the objective is this: we're bringing those two pieces of the interventional business together and integrating them fully. They're a really strong fit. This combined portfolio is outstanding. As all of you know, I've spent a very long time in this space. It's a phenomenal portfolio, and we need to get it moving in the right direction. What we're aiming for is continuous improvement, setting it up for a good 2027, making it better, getting it to market growth — which we discussed earlier — mid single digits, and setting it up for growth and success over the long term. We have a great pipeline, including potentially transformational products, the option equity of Freezsolve, so that's our objective, and again, I have high confidence in our ability to deliver because there is so much opportunity. Given where we currently stand in the market, plenty of people aren't yet aware now of this combined total Teleflex, so that's on us, but as we drive that forward, we've got plenty of chances to gain share; we've got plenty of chances to keep expanding geographically, where we have only a light presence in many parts of the world where the interventional business is quite penetrated. Again, we've got these really nice opportunities to gain growth with new product introduction, and we feel good about where that's going.
Travis Steed
analystGreat, thank you very much. This is sort of a follow-up question. In earlier calls, I believe the $11.25 and $11.50 in earnings had been somewhat endorsed, and I'm assuming that reflected full capital deployment on our part. I'm not sure — with the possible delay in the sale, is there a chance that's still fine, but you'd need to adjust it for the timing of capital deployment? Regarding the delay, I don't know whether something has changed there, or whether it's prudent at this point to keep some room in case it does get delayed?
Jason Weidman
executiveLet me take the last part first, and then I'll hand the EPS question over to John. On the divestiture of acute care and interventional urology, we remain very confident that this transaction will close. We are making progress. As we mentioned back in the spring and have discussed since, we received a second request, and it came about because of a small product overlap with the buyer's portfolio. The buyer is actively working on a remedy, and we are supporting that effort. We are working together collectively, and both parties — the buyer and us — are definitely targeting a close by the end of the year; it's just that, at this stage, and given that it's a regulatory process with some elements outside our control, we feel it's prudent to say that it is possible it could move into 2027. It has nothing at all to do with any change in our confidence in our ability to get this done — just where we are in the process. John. I
John Deren
executiveThanks for the EPS question. During last quarter's discussion, we were attempting to convey how optimistic we are about what earnings could look like in 2027, and I want to say that our optimism hasn't faded at all. With the leadership changes we've put in place and the trajectory all three businesses are on, we feel good about where things stand. On our capital allocation plan, execution has been extremely strong up to this point, and in our planning to remove stranded costs stemming from both divestitures, we've made meaningful progress. Once Q4 is behind us and the ISG deal has closed, we'll be well positioned to provide you with genuinely solid guidance for 2027.
Nathan Treybeck
analystGood morning. Nathan Treybeck here, sitting in for Larry. Could you discuss the improvement in gross and operating margin during Q3 once the tariff refund is excluded? The guidance appears to suggest operating margin will decline year-over-year in Q4, after holding flat in Q3 when the tariff refund is excluded. Can you explain just why margins look that way in Q4? Thanks.
John Deren
executiveLook, clearly, when you examine the tariffs against EPS and margins, it came to 290 basis points on margins, correct? That is, clearly, a one-time item. Regarding Q4, I'll tell you this: we do have a meaningful step-up planned in R&D expense; we're ramping up the BIOMAG-III studies. A number of significant start-up costs occur, so that accounts for some of the contraction we would see in Q4. That does not alter our view on the long-term op margin. Those are some start-up costs and, frankly, that's going to involve some timing in Q4. We feel quite confident in the margins and see the one-time item in tariffs helping us this quarter, and then a bit of one-time costs as we ramp up the BIOMAG-III studies, and there are also some additional investments in the business expected to happen in Q4 across the rest of the portfolio.
Nathan Treybeck
analystThat’s useful. You laid out three temporary factors behind the interventional shortfall. Could you rank those by revenue impact and say which ones are now completely resolved and which remain unresolved as we head into 2027?
Jason Weidman
executiveWell, ranking them isn’t something I’m going to do. I’d also note that some of these overlap in a Venn-diagram kind of way, and we don’t go into the specifics of trying to compute the precise revenue effect of each one. What I can say is that we keep making steady progress across all of them, and more work remains; take OTC transition, for example — as I mentioned, 90% of customers have made the move, and 10% are left; that ought to be completed in the near term. In the VI business, a substantial portion is consignment. Consignment was new to Teleflex, and we were and still are refining our processes and improving how we handle consignment and how we manage it; there is still work ahead. We’re performing well, but work remains to make it simpler and less demanding for our teams. On the distributor side, as I said, we’re roughly 87% of the way there in moving legacy distributors onto Teleflex contracts and turning them into Teleflex distributors, and a bit of work is left, though we are clearly improving; then from the sales force angle, we’ve made enormous progress filling the open roles, but naturally it takes, on average, 6 months before reps become productive, and reps are going through that training, and we’ll need to complete our final hiring, but we’re in good shape and heading the right way.
Ravi Misra
analystHi, good morning, and thanks for taking the questions. I suppose I'll start with the first one, just on guidance. The 4Q guide is a bit below consensus, and I appreciate that you gave some metrics around non-operating items and talked about a step-up in R&D here. Is there anything else we should be contemplating — for instance, could the potential delay of the asset close lead to transition services benefits being pushed out, and should we take that out of our models? Then, relatedly, when we think about 2027, the Street has growth acceleration for you at roughly just under the 5% range. You made a few comments on the bottom line in your prepared remarks. How should we think about the top line? Is that still the place to be? Thank you.
Jason Weidman
executiveFirst, I'll comment just on 2027, and then, John, I'll let you comment on Q4 and those specific guidance questions. The short answer is we're not going to give guidance on 2027 in this call. We'll do that on the next call; we're still working through everything going on in the business, going through our planning for next year, and we're not in a position to provide numbers for next year. We feel good about the direction we're going. We have a lot of opportunities ahead of us, and we'll update you on the next call about that.
John Deren
executiveOn the bottom line, I apologize that my numbers don't line up with everyone's consensus, but ultimately, we have raised our EPS guidance for operational items, and those have performed very well throughout the portfolio. We have never included anything in the past that we hadn't already entered into; there are no TSAs or MSAs related to the ISG deal that would appear in today's guidance. Those aren't factored into the guidance — there's no difference there and no hesitation, so to speak. There is some TSA and MSA income stemming from the OEM deal, and that will keep coming, and it's part of our guidance that will carry on through the close of the year and well into the following year. No, there's nothing beyond that which you haven't already heard.
Ravi Misra
analystThanks.
Lawrence Keusch
executiveThanks, Alexandra, and I appreciate all of you for being with us on today's call; that brings the Teleflex Incorporated Third Quarter 2026 Earnings Conference Call to a close.
Operator
operatorThis concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.